Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects

被引:84
作者
Amend, Bastian [1 ]
Hennenlotter, Joerg [1 ]
Schaefer, Tobias [1 ]
Horstmann, Marcus [1 ]
Stenzl, Arnulf [1 ]
Sievert, Karl-Dietrich [1 ]
机构
[1] Univ Tubingen, Dept Urol, D-72076 Tubingen, Germany
关键词
detrusor-sphincter-dyssynergia; neurogenic bladder; muscarinic antagonists; side-effects; tolterodine; trospium; oxybutynin; spinal cord injury;
D O I
10.1016/j.eururo.2008.01.007
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objectives: Patients with neurogenic bladder dysfunction demonstrate an insufficient treatment outcome under dosage-escalated monotherapy. With the objectives of continence and normalised bladder pressure, safe and tolerable non-invasive treatment alternatives were evaluated by using combined antimuscarinics. Methods: Twenty-seven patients who were previously registered in a doubled antimuscarinics study were enrolled in this study. The patients demonstrated urodynamic-proven neurogenic bladder dysfunction with incontinence, reduced bladder capacity, and increased intravesical pressure, resulting from spinal cord injury (n = 21); spinal cord dysplasia (myelomeningocele; n = 3); multiple sclerosis (n = 2), and viral encephalomyelitis (n = 1). on the basis of the initial study treatment, they were allocated into three groups and treated with two antimuscarinics. Before enrolment, at 4 wk, and at 6 mo, patients underwent urodynamics and recorded bladder diaries, including side-effects. Results: in all three groups, significant changes were noted at the 4-wk follow-up. Incontinence events decreased from an average of 7 to 1 event per day. The average median bladder capacity (180-393 ml) and reflex volume (125-335 ml) increased; detrusor compliance also improved (average, 15-33 ml/cm H2O). Seven patients reported side-effects; two discontinued the successful treatment. Two other patients did not reach satisfactory amelioration of the detrusor dysfunction. Conclusion: With combined high-dosage antimuscarinic medications, 85% of the patients who previously demonstrated unsatisfactory outcome with dosage-escalated monotherapy were treated successfully. The appearance of side-effects was comparable to that of normal-dosed antimuscarinics. Further studies are required to investigate the long-term pharmacological and physiological background of our findings. (c) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1021 / 1028
页数:8
相关论文
共 36 条
[1]
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]
ABRAMS P, 2005, INCONTINENCE, P1059
[3]
Antimuscarinics for treatment of overactive bladder [J].
Andersson, KE .
LANCET NEUROLOGY, 2004, 3 (01) :46-53
[4]
[Anonymous], UROLOGY
[5]
Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis [J].
Appell, RA .
UROLOGY, 1997, 50 (6A) :90-96
[6]
The newer antimuscarinic drugs: Bladder control with less dry mouth [J].
Appell, RA .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2002, 69 (10) :761-+
[7]
Pharmacotherapy for neurogenic detrusor overactivity [J].
Chancellor, Michael B. ;
Anderson, Rodney U. ;
Boone, Timothy B. .
AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2006, 85 (06) :536-545
[8]
Muscarinic receptor subtypes and management of the overactive bladder [J].
Chapple, CR ;
Yamanishi, T ;
Chess-Williams, R .
UROLOGY, 2002, 60 (5A) :82-88
[9]
Epstein BJ, 2006, AM FAM PHYSICIAN, V74, P2061
[10]
Fröhlich G, 2002, INT J CLIN PHARM TH, V40, P295